Gonococcal Arthritis Medication
- Author: Rachel Robbins, MD; Chief Editor: Herbert S Diamond, MD more...
The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications. Disseminated gonococcal infection (DGI) or gonococcal arthritis is treated with antibiotics.
Dual antibiotic regimens (preferably cetriaxone plus azithromycin) are indicated for treatment of gonococcal infection.
The 2015 CDC recommendations for disseminated gonococcal infection are :
Ceftriaxone 1 g IM/IV every 24 h plus a single dose of azithromycin 1 g PO
Alternative regimen - Cefotaxime 1 g IV every 8 h plus a single dose of azithromycin 1 g PO
When treating for the arthritis-dermatitis syndrome, the healthcare provider can switch to an oral agent guided by antimicrobial susceptibility testing 24-48 h after substantial clinical improvement, for a total treatment course of at least 7 days.
Ceftriaxone is the drug of choice for DGI or gonococcal arthritis, according to guidelines developed by the Centers for Disease Control and Prevention (CDC). It exerts its bactericidal action through inhibition of cell-wall synthesis. It has no activity against Chlamydia.
Azithromycin inhibits bacterial growth, possibly by blocking the dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest. It is part of the first-line preferred dual-drug regimen for disseminated gonococcal infections plus ceftriaxone IM/IV.
Cefotaxime is a third-generation cephalosporin used as an alternative to ceftriaxone for treatment of DGI or gonococcal arthritis. It exerts its bactericidal action through inhibition of cell-wall synthesis.
Dalla Vestra M, Rettore C, Sartore P, Velo E, Sasset L, Chiesa G, et al. Acute septic arthritis: remember gonorrhea. Rheumatol Int. 2008 Nov. 29(1):81-5. [Medline].
Bardin T. Gonococcal arthritis. Best Pract Res Clin Rheumatol. 2003 Apr. 17(2):201-8. [Medline].
Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am. 2005 Dec. 19(4):853-61. [Medline].
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2013. Atlanta, GA: U.S.Department of Health and Human Services; December 2014. [Full Text].
World Health Organization Fact Sheet Number 110. Available at http://www.who.int/mediacentre/factsheets/fs110/en/index.html. Accessed: April 13, 2014.
Belkacem A, Caumes E, Ouanich J, Jarlier V, Dellion S, Cazenave B, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect. 2013 Dec. 89 (8):613-5. [Medline].
Tuttle CS, Van Dantzig T, Brady S, Ward J, Maguire G. The epidemiology of gonococcal arthritis in an Indigenous Australian population. Sex Transm Infect. 2015 Mar 19. [Medline].
Marker-Hermann E. Septic arthritis, osteomyelitis, gonococcal and syphilitic arthritis. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 4th ed. Philadelphia, PA: Mosby Elsevier; 2008. 1013-28.
Low SY, Ong CW, Hsueh PR, Tambyah PA, Yeo TT. Neisseria gonorrhoeae paravertebral abscess. J Neurosurg Spine. 2012 Jul. 17(1):93-7. [Medline].
Davis BT, Pasternack MS. Case records of the Massachusetts General Hospital. Case 19-2007 - a 19-year-old college student with fever and joint pain. N Engl J Med. 2007 Jun 21. 356(25):2631-7. [Medline].
Liebling MR, Arkfeld DG, Michelini GA, Nishio MJ, Eng BJ, Jin T, et al. Identification of Neisseria gonorrhoeae in synovial fluid using the polymerase chain reaction. Arthritis Rheum. 1994 May. 37(5):702-9. [Medline].
Read P, Abbott R, Pantelidis P, Peters BS, White JA. Disseminated gonococcal infection in a homosexual man diagnosed by nucleic acid amplification testing from a skin lesion swab. Sex Transm Infect. 2008 Oct. 84(5):348-9. [Medline].
Kimmitt PT, Kirby A, Perera N, Nicholson KG, Schober PC, Rajakumar K, et al. Identification of Neisseria gonorrhoeae as the causative agent in a case of culture-negative dermatitis-arthritis syndrome using real-time PCR. J Travel Med. 2008 Sep-Oct. 15(5):369-71. [Medline].
Centers for Disease Control and Prevention. Notice to readers: discontinuation of spectinomycin. MMWR. 2006. 55:370.
Centers for Disease Control and Prevention. Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm. Accessed: April 13, 2014.
Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. MMWR Morb Mortal Wkly Rep. 2012 Aug 10. 61:590-4. [Medline].
[Guideline] Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR. 2006. 55(No. RR-11):42-49.
MMWR. Availability of Cefixime 400 mg tablets---United States, April 2008. Available at http://www.cdc.gov.mmwr/preview/mmwrhtml/mm5716a5.htm. Accessed: May 1, 2009.
[Guideline] Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. RR-12. 59:49-55. [Medline].
Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect. 2013 Dec. 89 Suppl 4:iv5-10. [Medline].
Roth A, Mattheis C, Muenzner P, Unemo M, Hauck CR. Innate recognition by neutrophil granulocytes differs between Neisseria gonorrhoeae strains causing local or disseminating infections. Infect Immun. 2013 Jul. 81(7):2358-70. [Medline].